Avantor (AVTR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
29 Apr, 2026Executive summary
Q1 2026 results exceeded expectations, with net sales of $1,581.4 million, flat year-over-year, and organic sales down 4.1% due to positive foreign currency impact.
Revival transformation program is delivering tangible operational improvements, increased accountability, and a refreshed leadership team by 25%.
Net income declined to $43.3 million from $64.5 million year-over-year, primarily due to lower operating income and higher SG&A expenses.
Adjusted EBITDA was $219.4 million (13.9% margin), down from $269.5 million (17.0% margin) in Q1 2025.
Full-year 2026 guidance reaffirmed, with confidence in returning to organic revenue growth in the second half.
Financial highlights
Q1 revenue: $1.581 billion, flat year-over-year; organic growth -4%.
Adjusted EBITDA: $219 million (13.9% margin); adjusted operating income: $191 million (12.1% margin).
Adjusted EPS: $0.17, ahead of expectations; diluted GAAP EPS: $0.06.
Free cash flow: $25 million ($39 million excluding restructuring costs), down from $82 million year-over-year.
Debt repayment: $105 million; adjusted net leverage ratio at 3.3x adjusted EBITDA.
Outlook and guidance
Q2 adjusted EPS expected between $0.19 and $0.20.
Full-year 2026 guidance reaffirmed, with organic revenue growth expected in the second half and adjusted EBITDA margin guidance of 14.8%–15.3%.
Adjusted EPS guidance of $0.77 to $0.83; free cash flow expected between $500M and $550M.
VWR organic growth expected to improve gradually, turning positive in the second half; BMP organic growth to bottom in Q2 and return to growth in H2.
Inflationary headwinds of $10–$20 million from Middle East conflict incorporated in guidance.
Latest events from Avantor
- All proposals passed, directors elected, and no questions raised during the meeting.AVTR
AGM 20267 May 2026 - Key votes include board elections, executive pay, and auditor ratification for 2026.AVTR
Proxy filing27 Mar 2026 - Proxy details leadership transitions, Revival strategy, and votes on directors, pay, and auditor.AVTR
Proxy filing27 Mar 2026 - Q3 2025 net loss of $711.8M on 5.3% lower sales; $500M buyback and cost actions announced.AVTR
Q3 202517 Mar 2026 - 2026 is a transition year with Revival investments, margin pressure, and strong free cash flow.AVTR
Q4 202511 Feb 2026 - Q2 2024 saw margin expansion, net income rebound, and reaffirmed full-year guidance.AVTR
Q2 20242 Feb 2026 - Cost transformation and innovation drive margin expansion and resilience amid cautious demand.AVTR
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Cost transformation and bioprocessing momentum support a positive growth outlook.AVTR
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 saw $1.71B revenue, strong cash flow, and raised FCF guidance amid cost transformation.AVTR
Q3 202418 Jan 2026